Home › Funds › Cormorant Asset Management, LP › CRNX

Cormorant Asset Management, LP position in CRNX

CRINETICS PHARMACEUTICALS IN

Cormorant Asset Management, LP reported holding 125,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$4.7M, representing 0.24% of its reported portfolio and ranking #39 among its reported holdings. Cormorant Asset Management, LP has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)125.00K sh
Reported value held$4.68M
Portfolio Weight0.24%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's CRNX position evolved

Cormorant Asset Management, LP first disclosed a stake in CRNX in Q3 2023 at 1,101,904 shares (US$32.8M). The position peaked in Q2 2024 at 1,350,000 shares, worth US$60.5M. Across 12 filings, Cormorant Asset Management, LP increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 125,000 shares valued at US$4.7M — a reduction of -125,000 shares quarter over quarter.. Notable position changes include a 40% trim in Q1 2025, a 33% trim in Q2 2025, a 50% trim in Q2 2026.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.10M $32.77M New
Q4 2023 1.15M $40.92M Add
Q1 2024 1.15M $53.83M Hold
Q2 2024 1.35M $60.47M Add
Q3 2024 1.10M $56.21M Reduce
Q4 2024 1.00M $51.13M Reduce
Q1 2025 600.00K $20.12M Reduce
Q2 2025 400.00K $11.50M Reduce
Q3 2025 400.00K $16.66M Hold
Q4 2025 300.00K $13.96M Reduce
Q1 2026 250.00K $9.08M Reduce
Q2 2026 125.00K $4.68M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has Cormorant Asset Management, LP held CRNX?

Cormorant Asset Management, LP has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Cormorant Asset Management, LP's current position in CRNX?

As of Q2 2026, Cormorant Asset Management, LP holds 125.00K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $4.68M, representing 0.24% of its reported portfolio and ranking #39.

Has Cormorant Asset Management, LP been buying or selling CRNX?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in CRNX. The position peaked in Q2 2024 at 1.35M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.